Latest News

  • Boehringer Ingelheim Teams Up With Brainomix, New Diagnostic For Multiple Sclerosis, More

    Diagnostics World | Researchers at The Australian National University (ANU) have developed a deep learning algorithm, known as DEPLOY, to classify central nervous system tumors into 10 major categories from histopathology images. The goal is to optimize treatment with a faster, more accessible diagnostic approach than the state-of-the-art practice of DNA methylation-based profiling, which can take weeks.

    Jul 25, 2024
  • Element Biosciences Commercializing Platform, NOWDiagnostics At-Home Tests, More

    Diagnostics World | Element Biosciences nets $277 million to launch combined sequencing and cyto-profiling platform; NOWDiagnostics raises $22.5 million for at-home diagnostic tests; and more.

    Jul 24, 2024
  • Grassroots Initiative Helping Clinicians Better Treat Rare Disease Patients

    Diagnostics World | A new web-based platform aims to standardize the care of rare disease patients in a wide range of settings and accelerate their diagnostic journey. The Rare Disease Clinical Activity Protocols (RareCAP) is effectively a collection of the latest research-based information and guidance about some of the more than 7,000 conditions affecting a small number of people.

    Jul 23, 2024
  • Cardiac Sarcoidosis: Exploring a Rare and Difficult-to-Diagnose Disease

    Diagnostics World | Most of the time, sarcoidosis appears in the lungs and lymph nodes, but the heart is impacted in a smaller number of patients. Known as cardiac sarcoidosis (CS), this rare condition can lead to serious complications like arrhythmia or heart failure. Recently, Diagnostics World covered efforts to improve diagnostic and treatment options for sarcoidosis.

    Jul 18, 2024
  • Digital Endpoints Gaining Ground in Industry-Sponsored Trials

    Diagnostics World | A recent analysis of interventional clinical trials by the Tufts Center for the Study of Drug Development (CSDD) has found that use of digital endpoints has been growing rapidly since 2015 with drug developers now initiating an average of about 35 such studies each year. News of the uptick isn’t entirely surprising, given mounting evidence that the approach can improve operational performance and ease patient burdens in clinical trials and in clinical practice, while [potentially] yielding financial net benefits to developers.

    Jul 16, 2024